PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-95.21%
Revenue decline while AXSM shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
31.39%
Cost growth less than half of AXSM's 215.32%. David Dodd would verify if cost advantage is structural.
-116.81%
Gross profit decline while AXSM shows 2614.27% growth. Joel Greenblatt would examine competitive position.
-451.18%
Margin decline while AXSM shows 0.00% expansion. Joel Greenblatt would examine competitive position.
6.71%
R&D growth less than half of AXSM's 25.48%. David Dodd would verify if efficiency advantage is sustainable.
86.34%
G&A growth above 1.5x AXSM's 21.23%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
29.34%
Operating expenses growth 1.1-1.25x AXSM's 25.04%. Bill Ackman would demand justification.
29.34%
Similar total costs growth to AXSM's 27.61%. Walter Schloss would investigate norms.
-100.00%
Interest expense reduction while AXSM shows 68.09% growth. Joel Greenblatt would examine advantage.
31.39%
D&A growth less than half of AXSM's 308.20%. David Dodd would verify if efficiency is sustainable.
-52.58%
EBITDA decline while AXSM shows 0.18% growth. Joel Greenblatt would examine position.
-3087.14%
EBITDA margin decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
-52.01%
Both companies show declining income. Martin Whitman would check industry conditions.
-3075.40%
Operating margin decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
137.14%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
-51.43%
Both companies show declining income. Martin Whitman would check industry conditions.
-3063.27%
Pre-tax margin decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
100.00%
Tax expense growth above 1.5x AXSM's 4.02%. Michael Burry would check for concerning trends.
-52.47%
Both companies show declining income. Martin Whitman would check industry conditions.
-3085.00%
Net margin decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
-43.48%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-43.48%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
7.17%
Share count reduction below 50% of AXSM's 1.98%. Michael Burry would check for concerns.
7.17%
Diluted share reduction below 50% of AXSM's 1.98%. Michael Burry would check for concerns.